The company said it would further like to penetrate into segments like fragrances and flavours, food and beverages, etc. in which new products will be launched in the immediate future.
Pravin Herlekar, Chairman and Managing Director of the company told CNBC-TV18 that the patent, fourth one for the firm, is for beta ketoester chemical. There are seven more patents in the pipeline, he added.
Omkar Speciality Chemicals' whole time director Omkar P Herlekar is confident of logging a growth rate above industry standards for FY16.
Speciality chemicals manufacturer eyes revenue growth of 20-25 percent in FY15, says CMD Pravin Herlekar, adding that the company will maintain profit after tax (PAT) margins of 7-8 percent in this fiscal, which will improve in FY16.
Pravin Herlekar, the chairman and managing director of Omkar Speciality Chemicals says LASA Lab is an attractive buy for the company as it is an established player in the API segment.
In an interview with CNBC-TV18, Pravin Shivdas Harlekar, MD, Omkar Speciality said the company’s existing capacity is 950 metric tonne. “By FY13, we would like to expand up to 3,650 metric tonne per year,” he added.
Omkar Speciality Chemicals saw a strong profit growth in FY11. Speaking exclusively to CNBC-TV18, the company’s managing director Pravin Shivdas Harlekar says that the company that manufactures specialty chemicals is likely to “maintain the trend.”
In an interview with CNBC-TV18, Pravin Shivdas Harlekar, MD, Omkar Speciality says, the company is targeting atleast 45% revenue growth in FY12.
In an exclusive interview with CNBC-TV18’s Soniya Shenoy and Ekta Batra, Pravin Shivdas Harlekar, Chairman and Managing Director of Omkar Speciality says that the company is confident of a 45% growth in revenues in FY11. “The target is to cross Rs 150 crore in 2011-12,” he says.